Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 3;12(12):e11886.
doi: 10.7759/cureus.11886.

Clinical Outcomes After Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer: A Single Institutional Study

Michael Abdalmassih  1 , Oliver Bucher  2 , Shrinivas Rathod  3 , Arbind Dubey  3 , Julian O Kim  3 , Naseer Ahmed  3 , Ahmet Leylek  3 , Amitava Chowdhury  3 , Bashir Bashir  3
Affiliations

Clinical Outcomes After Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer: A Single Institutional Study

Michael Abdalmassih et al. Cureus. .

Abstract

Introduction The standard of care for early-stage non-small cell lung cancer (NSCLC) is surgery. However, for medical inoperable patients stereotactic body radiation therapy (SBRT) is an alternative method. The aim of the study is to assess the overall survival (OS), progression-free survival (PFS) and local control (LC) of patients diagnosed with NSCLC in Manitoba, Canada, between 2013 and 2017 and managed with SBRT. Materials and methods This retrospective study included a total of 158 patients (60.13% of the population were females) that were diagnosed with stage I-II NSCLC and were treated with lung SBRT between 2013 and 2017 in Manitoba. Demographics and clinical data were retrospectively extracted from the electronic patient record. Kaplan-Meier and Cumulative incidence curves were used to describe the OS, PFS, and LC outcomes. Results From the 158 patients, 32 patients were treated with 60 Gy in eight fractions, while 121 patients were treated with 48 Gy in four fractions. Only 85 patients had biopsy-proven NSCLC. The median OS was 2.87 years (95% confidence interval [CI] 2.16-3.43). OS rates at one and two years were 85% and 66%, respectively. The median PFS was 2.03 years (95% CI 1.65-2.77). Furthermore, one-year and two-year PFS rates were 77% and 51%, respectively. Only 10 patients progressed locally at one year and 17 at two years, making the LC rate 93% at the one-year and 87% at the two-year mark. Conclusion These findings add to a growing evidence base supporting SBRT in the treatment of clinically suspected and biopsy-proven early-stage NSCLC patients.

Keywords: lung cancer; nsclc; sbrt; stereotactic radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Kaplan-Meier curve of overall survival for the whole study cohort (n = 158)
Figure 2
Figure 2. Kaplan-Meier curve of progression-free survival for the whole study cohort (n = 158)
Figure 3
Figure 3. Cumulative incidence curve of local progression for the whole study cohort (n = 158)
See this image and copyright information in PMC

References

    1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Ferlay J, Colombet M, Soerjomataram I, et al. Int J Cancer. 2019;144:1941–1953. - PubMed
    1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Canadian Cancer Statistics: A 2018 Special Report on Cancer Incidence by Stage. [Aug;2020 ];Canadian Cancer Society: Canadian Cancer Statistics Advisory Committee. (2018. https://www.cancer.ca/~/media/cancer.ca/CW/publications/Canadian%20Cance... 2018
    1. Recommendations on screening for lung cancer. Canadian Task Force on Preventive Health Care. CMAJ. 2016;188:425–432. - PubMed
    1. Reduced lung-cancer mortality with low-dose computed tomographic screening. National Lung Screening Trial Research Team. N Engl J Med. 2011;365:395–409. - PMC - PubMed

LinkOut - more resources